Back to Authors

Ibrahim, Nageatte

https://orcid.org/0000-0003-0794-949X

A5037357027 | I1285764155

Mayo Clinic

Merck & Co., Inc., Rahway, NJ, USA (United States)

Citations 1

5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 9516-9516

10.1200/jco.2018.36.15_suppl.9516